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1. Introduction 
As the world population has aged, the number of people affected by Alzheimer Disease is 
rapidly increasing in the world. It is important for clinicians to recognize early signs and 
symptoms of dementia and to note potentially modifiable risk factors and early disease 
markers.  
Accumulation of A┚ peptides may be the key event in pathogenesis of AD. The exact 
mechanism by which A┚ peptide deposition induces neurotoxicity is unclear, but it appears 
the oxidative stress plays an important role. Oxidative stress is extensive in AD and A┚ 
peptides stimulate oxidative stress by both direct and indirect mechanisms. A┚ peptides by 
themselves may act as enzymes and can bind to mitochondrial proteins resulting in the 
generation of free radicals. Furthermore, A┚ peptides generate oxidative stress via 
neuroinflammation. Considerable evidence has supported that neuroinflammation is 
associated with AD pathology. In addition, in AD, vascular injury and parenchymal 
inflammation perpetuate the cycle of protein aggregation and oxidation in the brain, and 
diffuse pathological changes include cerebral amyloid angiopathy, affecting more than 90% 
of patients with Alzheimer’s disease, capillary abnormalities, disruption of the blood-brain 
barrier, and large-vessel. In addition, it was reported that clearance of A┚ along diseased 
perivascular channels and through the blood-brain barrier is impeded in AD atheroma and 
that deregulation of A┚ transport across the capillary blood–brain barrier is caused by the 
imbalanced expression of low-density lipoprotein receptor-related proteins and receptors 
for advanced glycation end products. Besides, insulin resistance and hyperinsulinemia are 
implicated in a number of pathophysiological processes related to AD. It was demonstrated 
that reduced brain insulin signaling is associated with increased tau phosphorylation and 
A┚ levels in a streptozotocin induced model of diabetes mellitus. Moreover, insulin 
promotes the release of intracellular A┚ in neuronal cultures and accelerates A┚ trafficking 
to the plasma membrane. In addition, impaired insulin or insulin like growth factor-1  
(IGF-1) signaling can result in the hyper-phosphorylation of tau, which can cause cell death 
mediated by apoptosis, mitochondrial dysfunction or necrosis and promote oxidative stress, 
which contributes to the neurodegeneration cascade and leads to dementia-associated 
behavioral and cognitive deficits.  
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In shortly, the current pathophysiological approach to LOAD are based on a number of 
common mechanisms of neurodegeneration, such as accumulation of abnormal proteins, 
mitochondrial dysfunction and oxidative stress, impaired insulin signaling, calcium 
homeostasis dysregulation, early synaptic disconnection and late apoptotic cell death. Aging 
itself is associated with mild cognitive deterioration, probably due to subtle multifactorial 
changes resulting in a global decrease of a functional brain reserve.  
2. Pathophysiology of late onset Alzheimer disease 
As the world population has aged, dementia has become a common diagnosis in aging 
populations and the numbers will increase in the forthcoming years. Nowadays, the number 
of people affected by Alzheimer Disease (AD) is rapidly increasing in the world. AD is an 
age-related progressive neurodegenerative disorder presented by memory loss and severe 
cognitive decline (Isik & Bozoglu, 2010). 
AD is characterized by extensive atrophy of the brain caused by a series neuropathologic 
change, including neuronal loss, intracellular neurofibrillary tangles (NFTs) made up of Tau 
protein, extracellular senile plaques formed by ┚-amyloid (A┚) and synaptic loss (Ballatore 
et al., 2007 & Haass  Selkoe, 2007). Amyloid plaques and NFT result from an aberration in 
deposition of the A┚ peptide and the hyperphosphorylated tau protein, respectively, and 
these depositions lead to neuronal loss and neurotoxicity in the brain affected by AD (Isik, 
2010). However, plaques and NFTs are not unique to AD, as these same structural changes 
occur with normal aging and in many others neurodegenerative disorders (Jackson-Siegal, 
2005). Great confusion existed as to whether the dementia often observed in normal aging 
and AD were the same or different entities. It took nearly a century to define that the 
plaques were composed primarily of a specific peptide initially named A4 and today 
referred to as A┚ and that tangles are composed primarily of hyperphosphorylated forms of 
tau, a microtubule-associated protein. Tau is a protein known to stabilize microtubules 
present primarily in axonal processes and involved in axonal transport of subcellular 
components. The abnormal phosphorylation of this microtubule-related protein leads to 
molecular protein structures called paired helical filaments (PHFs), which constitute the 
ultrastructural core of the microscopic structures recognized as NTFs. Most contemporary 
research on the molecular basis of the disease has focused chiefly on these two proteins, and 
the causality of the disease has been attributed to either or both of these proteins. For a 
while, the two camps of thought were humorously referred to as the Baptists (for A┚) and 
the Taoists (for tau) (Cuello, 2007). A distinguishing feature of AD is that the plaques and 
NFTs are localized to areas in the brain corresponding to the clinical symptoms. Although 
the development of plaques and NFTs eventually leads to a noticeable clinical condition, the 
process is thought to start years before the initial onset of symptoms (Jackson-Siegal, 2005). 
3. Risk factors  
Great number of nongenetic risk factors have been identified or proposed for the sporadic 
form of the disease. Of these, unequivocally, aging is the most relevant. To define between 
the AD and aging, that AD might reflect a continuum of the brain aging can be proposed. In 
other words, given the opportunity, every individual should eventually succumb to AD. 
This view can be supported by the undeniable fact that aging is the most important of the 
nongenetic risk factors as shown by the ever growing incidence of AD with aging. On the 
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other hand, the prevalent notion is that the incidence of AD is influenced by a multitude of 
risks factors in addition to aging, which might act in a cooperative manner. The extent of the 
life span could also be regulated by the genetic background interacting with environmental 
as well as lifestyle aspects. The role of genetics in determining the life span is complex and 
paradoxical. In short, the prevalent view is that for the sporadic form of AD, it is not 
necessarily all in the genes but rather interplay with the life experience of that particular 
individual. The molecular mechanisms of brain aging remain elusive. Several molecular 
events are suspects in the age-related downfall of brain function, which might be linked to 
the earlier appearance of AD. Some researchers have paid attention to low levels of vitamin 
B complex and the plasma elevation of homocysteine, as being responsible for age-related 
cognitive deficits and unleashing the AD pathology (Cuello, 2007). Furthermore, our results 
demonstrated that replacement and close follow up of vitamin B12 deficiency are crucial in 
the elderly population regardless of any disturbance in the hematological parameters 
(Bozoglu et al., 2010).  
While early onset AD is almost genetically based, there are no specific gene mutations 
that are associated with inheritance of the disease in late onset AD (LOAD). The 
expression of the apolipoprotein E (ApoE) 4 allele is one of the risk factors identified for 
LOAD. In the central nervous system, ApoE is synthesized by astrocytes, microglia, and, 
to a lesser extent, by neurons. The role of ApoE in LOAD pathogenesis is not fully 
elucidated, but it has been suggested that ApoE is very important in trafficking of 
amyloid ┚ (A┚) peptide. In addition, apolipoprotein J (clusterin), an amyloid ┚-peptide 
chaperone, TOMM40, a transporter of proteins across the mitochondrial membrane, and 
Sortillin-related receptor, which functions to partition amyloid precursor protein away 
from ┚-secretase and ┛-secretase, are recently discovered proteins encoded by the risk 
genes for LOAD. However, it was reported that higher plasma concentrations of clusterin 
correlate significantly with the presence and severity of AD but doesn’t correlate with the 
risk for onset of the disease (Schrijvers et al, 2011). 
In addition to nonmodifiable genetic risk factors, potentially modifiable factors, such as 
hypertension, diabetes mellitus, hyperlipidemia, hyperhomocysteinemia, coronary and 
peripheral artery diseases, alcohol, smoking, obesity, levels of physical or mental activity, 
levels of education, and environmental exposures have been investigated to identify risk 
factors for LOAD. Furthermore, it has been reported that risk index methods including these 
risk factors provide a practical, flexible, and objective framework for identifying the optimal 
combination of measures for identification of high-risk individuals for prevention and early 
intervention efforts. Despite the personal and social burden of LOAD, our understanding of 
the genetic predisposition to LOAD and the contribution of other risk factors remains 
limited. More importantly, there are few data to explain the overall risks and benefits of 
prevention strategies or their impact on risk modification (Isik, 2010; Querfurth & La Ferla, 
2010).  
4. Pathogenesis 
The amyloid material was initially thought to be systemically derived from serum proteins 
and characterized as a short peptide (9). A┚ peptides are natural products of metabolism 
consisting of 36 to 43 amino acids. Monomers of A┚40 are more prevalent than the 
aggregation-prone and damaging A┚42 species. ┚-amyloid peptides originate from 
proteolysis of the amyloid precursor protein (APP) lodged in cell membranes by the 
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sequential enzymatic actions of beta-site amyloid precursor protein–cleaving enzyme 1 
(BACE-1), a ┚-secretase, and ┛-secretase, a protein complex with presenilin 1 at its catalytic 
core (Cuello, 2007). In this process the release of A┚ peptides is achieved by the consecutive 
action of a ┚-secretase cleaving APP at the N-terminal site of the A┚ domain, followed by its 
cleavage at the ┛-secretase site at the C-terminal end, thus generating A┚ fragments of 
diverse lengths, but typically of 40 and 42 amino acids in length. The longer peptide, A┚ 1-
42, is more neurotoxic and more prone to aggregation and amyloidogenic. The ┚- and ┛-
secretases have been identified and cloned. Two proteins are currently recognized with ┚-
secretase functions. They are named BACE 1 and 2, of which BACE 1 appears to be more 
important for the development of the AD pathology (Vassar & Citron, 2000). The ┚-
secretases release a large peptide which in biochemical jargon is referred to as C99, 
containing both the A┚ motif and another motif defined as AICD (APP internal C-terminal 
domain). The ┛-secretase site is more complex. Initially, it was proposed that presenilins 
(mutations of which were already known to cause familial forms of AD) were the actual ┛-
secretase. Today, there is consensus that the ┛-secretase site is composed of an ensemble of 
proteins, some of which might be responsible for the modulation of the APP-catalytic 
activity preselinins 1 and 2. This complex has the peculiarity of being capable of a catalytic 
action in the fairly hydrophobic milieu of cell and organelle membranes (Cuello, 2007).The 
catalytic activity of the ┛-secretase action is ultimately responsible for the liberation of the 
amyloidogenic A┚ peptide and the AICD fragment (Wolfe, 2006). AICD is suspected to 
either act as a transcription factor or be involved in cell signaling mechanisms in the CNS, 
however, its actual biological significance is still being debated (Cuello, 2007). Finally, an 
imbalance between production and clearance, and aggregation of peptides, causes A┚ to 
accumulate, and this excess may be the initiating factor in Alzheimer’s disease. This idea, 
called the “amyloid hypothesis,” is based on studies of genetic forms of AD, including 
Down’s syndrome, and evidence that A┚42 is toxic to cells (Querfurth & La Ferla, 2010).  
Amyloid plaques, together with NFTs, occur in AD and other neurodegenerative 
disorders, in addition to normal aging (Guillozet et al., 2003).  The number of NFTs is a 
pathologic marker of the severity of AD. The major component of the tangles is an 
abnormally hyperphosphorylated and aggregated form of tau. Normally an abundant 
soluble protein in axons, tau promotes assembly and stability of microtubules and vesicle 
transport. Hyperphosphorylated tau is insoluble, lacks affinity for microtubules, and self-
associates into paired helical filament structures. Enzymes that add and those that remove 
phosphate residues regulate the extent of tau phosphorylation (8). These NFTs have a 
clear-cut temporal and topographic distribution across brain areas as the disease 
progresses. The best staging of such structures has been provided by Braak and Braak 
(Braak H& Braak E, 1998). Interestingly, the earliest Braak stage is the occurrence of NFTs 
in the entorhinal cortex in the absence of an obvious deposition of A┚ material in this 
brain region. This observation has been used as an argument to dissociate tau from A┚ 
pathology in AD. The causal relation between these two molecular pathologies remains 
uncertain (Cuello, 2007).  
The amyloid cascade hypothesis posits that A┚ triggers Tau pathology, but the details of this 
relationship are still poorly understood. Accumulation of A┚ peptides may be the key event 
in the pathogenesis of AD and experimental models have suggested that exposure of 
neurons to A┚ is toxic and elicits abnormal changes in Tau (Garg et al., 2011). Although new 
imaging techniques and powerful animal models have helped understanding the time 
course and the mechanisms of the lesions, the relationship between A┚ accumulation and 
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tau pathology is still badly understood and the mechanism of LOAD continues to be 
debated (4). In some studies, the changes in Tau were ascribed to a toxic Tau fragment of 17 
kD generated by calpain cleavage and located in the N-terminal half of Tau, but other N-
terminal parts of Tau were reported to be toxic as well. In these cases, the toxicity could be 
triggered by A┚, but there was no apparent relationship to the aggregation of Tau. By 
contrast, studies on other cleavage reactions had shown that truncation of Tau in the C 
terminal domain by caspase-3 or by lysosomal proteases could generate Tau fragments with 
a high tendency for aggregation (Garg et al., 2011).  
Data obtained by electron microscopy and immunocytochemical and biochemical 
analysis on synaptic marker proteins in AD biopsies and autopsies indicate that synaptic 
loss in the hippocampus and neocortex is an early event and the major structural 
correlate of cognitive dysfunction. From all cortical areas analyzed, the hippocampus 
appears to be the most severely affected by the loss of synaptic proteins, while the 
occipital cortex is affected least. Although the cause for this failure is still unknown, 
recent evidence indicates a link between plastic synaptic changes and control of 
differentiation and cell cycle-repression within a neuron (Arendt, 2009). In mild 
Alzheimer’s disease, there is a reduction of about 25% in the presynaptic vesicle protein 
synaptophysin (Querfurth & La Ferla, 2010) and there is evidence that living neurons 
lose their synapses in AD. Furthermore, synaptic function is impaired in living neurons, 
as demonstrated by decrements in transcripts related to synaptic vesicle trafficking 
(Coleman & Yao, 2003).  
The exact mechanism by which A┚ peptide deposition induces neurotoxicity is unclear, 
but it appears that oxidative stress plays an important role. Besides, A┚ is a potent 
mitochondrial poison, especially affecting the synaptic pool. In AD, exposure to A┚ 
inhibits key mitochondrial enzymes in the brain and in isolated mitochondria. 
Cytochrome c oxidase is specifically attacked. Consequently, electron transport, ATP 
production, oxygen consumption, and mitochondrial membrane potential all become 
impaired (Querfurth & La Ferla, 2010). Consequently, oxidative stress is extensive in AD, 
and A┚ peptides stimulate oxidative stress by both direct and indirect mechanisms. A┚ 
peptides by themselves may act as enzymes and can bind to mitochondrial proteins, 
resulting in the generation of free radicals (Lustbader et al., 2004; Newman et al., 2007) A┚ 
peptides also generate oxidative stress via neuroinflammation. Considerable evidence has 
supported the hypothesis that neuroinflammation is associated with AD pathology 
(Newman et al., 2007).  
Interestingly, AD was speculated as the brain equivalent of non-insulin-dependent 
diabetes mellitus (Hoyer, 1998; Craft et al., 2000).  It was demonstrated that reduced brain 
insulin signaling is associated with increased tau phosphorylation and A┚ levels in a 
Streptozotocin induced model of diabetes mellitus, and also insulin promotes the release 
of intracellular A┚ in neuronal cultures and accelerates A┚ trafficking to the plasma 
membrane. Similarly, Intravenous insulin infusion also raised plasma A┚42 levels in 
patients with AD but not in normal adults, an effect that was exaggerated in patients with 
AD with higher body mass indexes. In addition, impaired insulin or IGF-1 signaling can 
result in the hyper-phosphorylation of tau, which can cause cell death mediated by 
apoptosis, mitochondrial dysfunction or necrosis and promote oxidative stress, which 
contributes to the neurodegeneration cascade, and leads to dementia-associated 
behavioral and cognitive deficits. For this reason, it seems that insulin resistance causes 
Tau phosphorylation and neurofibrillary tangle formation and increased beta amyloid 
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aggregation in late onset AD (1). In a recent study, Zhao and Townsend are demonstrated 
that insulin resistance and A┚ disrupt common signal transduction cascades including the 
insulin receptor family/Phosphoinositide 3-kinase/Akt/Glycogen synthase kinase-
3(GSK3) pathway. They reported that both disease processes contribute to overlapping 
pathology, thereby compounding disease symptoms and progression (Zhao & Townsend, 
2009). Besides, Proctor and Gray reported that GSK3┚ over activity leads to an increase in 
levels of A┚ plaques and tau tangle (Weller et al., 2009).The age-associated decline in the 
metabolic rate and utilization of glucose by the frontal cortex imply that insulin resistance 
can cause executive dysfunctions in older people, not only global cognitive impairment. 
Insulin resistance may cause decreased cortical glucose utilization especially in 
hippocampus and entorhinal cortex and also increased oxidative stress with advanced 
glycation end-products. In humans, raising plasma insulin levels through intravenous 
infusion increased cerebrospinal fluid levels of the A┚ 42 peptide; this effect was 
exacerbated by age. That insulin may interfere with A┚ degradation via its regulation of 
the metalloprotease insulin-degrading enzyme (IDE) may also be an important 
mechanism in late-onset AD that the A┚ clearance rather than A┚ production may be of 
special importance. Actually, the A┚-degrading capacity of IDE in the Alzheimer Disease 
brains is about 50% of that of control brains, but insulin degradation decreases by about 
30% only. Decreased IDE mRNA and IDE activity have been found in the hippocampus of 
late-onset AD brains; however, in neurons adjacent to senile plaques, IDE is up-regulated 
(Isik & Bozoglu, 2010). 
Furthermore, in AD, vascular injury and parenchymal inflammation perpetuate the cycle of 
protein aggregation and oxidation in the brain, and diffuse pathologic changes include 
cerebral amyloid angiopathy, affecting more than 90% of patients with AD, capillary 
abnormalities, disruption of the blood-brain barrier, and large-vessel channels (Querfurth & 
La Ferla, 2010; Price et al., 2001). It has also been reported that clearance of A┚ along 
diseased perivascular channels and through the blood-brain barrier is impeded in AD 
atheroma, (Deane & Zlokovic, 2007) and that deregulation of A┚ transport across the 
capillary blood–brain barrier is caused by the imbalanced expression of low-density 
lipoprotein receptor-related proteins and receptors for advanced glycation end products 
(Price et al., 2001; Proctor  & Gray 2010). 
The calcium hypothesis of AD proposes that activation of the amyloidogenic pathway 
remodels the neuronal Ca(2+) signalling pathways responsible for cognition by enhancing 
the entry of Ca(2+) and/or the release of internal Ca(2+) by ryanodine receptors or InsP(3) 
receptors. The specific proposal is that Ca(2+) signalling remodelling results in a persistent 
elevation in the level of Ca(2+) that constantly erases newly acquired memories by 
enhancing the mechanism of long-term depression. Neurons can still form memories 
through the process of long term potentiation, but this stored information is rapidly 
removed by the persistent activation of long-term depression. Further dysregulation in 
Ca(2+) signalling will then go on to induce the neurodegeneration that characterizes the 
later stages of dementia (Berridge, 2010). 
Finally, the current pathophysiologic approach to LOAD is based on a number of 
common mechanisms of neurodegeneration, including accumulation of abnormal 
proteins, mitochondrial dysfunction, and oxidative stress, impaired insulin signaling, 
calcium homeostasis dysregulation, early synaptic disconnection, and late apoptotic cell 
death. Aging itself is associated with mild cognitive deterioration, probably due to subtle 
multifactorial changes resulting in a global decrease of functional brain reserve. 
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